Clinical Trial · NCT07833085

CAIX-targeted PET/CT in Solid Tumors

Overview

Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.

Sponsor

Zhongnan Hospital

Phase

N/A

Contacts

Chongjiao Li, MD, PhD (CONTACT)

lcj0301@163.com

+86-27-67812698

Yong He, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07833085

Eligibility

Inclusion

Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology;
The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points;

Exclusion

Pregnant or lactating women;
Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans;
Other situations that researchers believe should be excluded and documented.
Participants with severe liver and kidney dysfunction and cardiac dysfunction;